Maarten Loos1, Thomas Mueller2, Yvonne Gouwenberg3, Ruud Wijnands1, Rolinka J van der Loo1, Carmen Birchmeier2, August B Smit3, Sabine Spijker4. 1. Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University Amsterdam; Sylics (Synaptologics BV), Amsterdam, The Netherlands. 2. Department of Developmental Biology, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany. 3. Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University Amsterdam. 4. Department of Molecular and Cellular Neurobiology, Center for Neurogenomics and Cognitive Research, Neuroscience Campus Amsterdam, VU University Amsterdam. Electronic address: s.spijker@vu.nl.
Abstract
BACKGROUND: A deficit in impulse control is a prominent, heritable symptom in several psychiatric disorders, such as addiction, attention-deficit/hyperactivity disorder, and schizophrenia. Here, we aimed to identify genes regulating impulsivity, specifically of impulsive action, in mice. METHODS: Using the widely used 5-choice serial reaction time task, we measured impulsive action in 1) a panel of 41 BXD recombinant inbred strains of mice (n = 13.7 ± .8 per strain; n = 654 total) to detect underlying genetic loci; 2) congenic mice (n = 23) to replicate the identified locus; 3) mice overexpressing the Nrg3 candidate gene in the medial prefrontal cortex (n = 21); and 4) a Nrg3 loss-of-function mutant (n = 59) to functionally implicate the Nrg3 candidate gene in impulsivity. RESULTS: Genetic mapping of impulsive action in the BXD panel identified a locus on chromosome 14 (34.5-41.4 Mb), syntenic with the human 10q22-q23 schizophrenia-susceptibility locus. Congenic mice carrying the impulsivity locus (Impu1) confirmed its influence on impulsive action. Increased impulsivity was associated with increased Nrg3 gene expression in the medial prefrontal cortex (mPFC). Viral overexpression of Nrg3 in the mPFC increased impulsivity, whereas a constitutive Nrg3 loss-of-function mutation decreased it. CONCLUSIONS: The causal relation between Nrg3 expression in the mPFC and level of impulsive action shown here provides a mechanism by which polymorphism in NRG3 in humans contributes to a specific cognitive deficit seen in several psychiatric diseases, such as addiction, attention-deficit/hyperactivity disorder, and schizophrenia.
BACKGROUND: A deficit in impulse control is a prominent, heritable symptom in several psychiatric disorders, such as addiction, attention-deficit/hyperactivity disorder, and schizophrenia. Here, we aimed to identify genes regulating impulsivity, specifically of impulsive action, in mice. METHODS: Using the widely used 5-choice serial reaction time task, we measured impulsive action in 1) a panel of 41 BXD recombinant inbred strains of mice (n = 13.7 ± .8 per strain; n = 654 total) to detect underlying genetic loci; 2) congenic mice (n = 23) to replicate the identified locus; 3) mice overexpressing the Nrg3 candidate gene in the medial prefrontal cortex (n = 21); and 4) a Nrg3 loss-of-function mutant (n = 59) to functionally implicate the Nrg3 candidate gene in impulsivity. RESULTS: Genetic mapping of impulsive action in the BXD panel identified a locus on chromosome 14 (34.5-41.4 Mb), syntenic with the human 10q22-q23 schizophrenia-susceptibility locus. Congenic mice carrying the impulsivity locus (Impu1) confirmed its influence on impulsive action. Increased impulsivity was associated with increased Nrg3 gene expression in the medial prefrontal cortex (mPFC). Viral overexpression of Nrg3 in the mPFC increased impulsivity, whereas a constitutive Nrg3 loss-of-function mutation decreased it. CONCLUSIONS: The causal relation between Nrg3 expression in the mPFC and level of impulsive action shown here provides a mechanism by which polymorphism in NRG3 in humans contributes to a specific cognitive deficit seen in several psychiatric diseases, such as addiction, attention-deficit/hyperactivity disorder, and schizophrenia.
Authors: Bart R Lubbers; Mariana R Matos; Annemarie Horn; Esther Visser; Rolinka C Van der Loo; Yvonne Gouwenberg; Gideon F Meerhoff; Renato Frischknecht; Constanze I Seidenbecher; August B Smit; Sabine Spijker; Michel C van den Oever Journal: Neuropsychopharmacology Date: 2015-12-29 Impact factor: 7.853
Authors: Clare Paterson; Yanhong Wang; Thomas M Hyde; Daniel R Weinberger; Joel E Kleinman; Amanda J Law Journal: Am J Psychiatry Date: 2016-10-24 Impact factor: 18.112
Authors: Zackary A Cope; Adam L Halberstadt; Jordy van Enkhuizen; Aaron D Flynn; Michelle Breier; Neal R Swerdlow; Mark A Geyer; Jared W Young Journal: Psychopharmacology (Berl) Date: 2016-08-17 Impact factor: 4.530
Authors: Luyi Zhou; Miranda L Fisher; Robert D Cole; Thomas J Gould; Vinay Parikh; Pavel I Ortinski; Jill R Turner Journal: Neuropsychopharmacology Date: 2017-11-07 Impact factor: 7.853